徐州医科大学附属宿迁医院甲型和乙型流感住院儿童的临床特征研究

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (638 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the epidemiological characteristics,clinical characteristics and the efficacy of Peramivir in hospitalized children with influenza A and B at the Affiliated Suqian Hospital of Xuzhou Medical University.Methods A total of 260 hospitalized children with influenza admitted to Affiliated Suqian Hospital of Xuzhou Medical University from January 2019 to August 2022 were retrospectively selected as the study objects,and were divided into influenza A group(130 cases)and influenza B group (130 cases)according to the results of influenza nucleic acid detection.All children were treated with intravenous Peramivir.The epidemiological characteristics of influenza A and influenza B in the two groups were analyzed,and the clinical symptoms,influenza complications,hematological indexes and clinical efficacy of Peramivir in the two groups were compared.Results Influenza B generally prevailed from November to March of the following year,influenza A mostly prevailed from November to January of the following year.However,the influenza A of 2022 outbroken in July.The proportion of fever and convulsions in influenza A group were higher than those in influenza B group,and the differences were statistically significant(P＜0.05).While the proportion of vomiting in influenza B group was higher than that in influenza A group,and the differences were statistically significant (P＜0.05).The proportion of neutropenia,febrile convulsion and leukopenia in influenza A group was higher than that in influenza B group,and the differences were statistically significant (P＜0.05).The proportion of pneumonia and viral encephalitis in influenza B group was higher than that in influenza A group,and the difference was statistically significant(P＜0.05).The lymphocyte percentage in influenza A group was lower than that in influenza B group,and the difference was statistically significant (P＜0.05).The time of fever symptom relief in influenza A group was shorter than that in influenza B group,and the difference was statistically significant (P＜0.05).The hospital stay of children with influenza B was longer than that of children with influenza A,and the difference was statistically significant (P＜0.001).Conclusion Children with influenza A were prone to fever and convulsions,and children with influenza B were more likely to vomit.The more frequent complications of influenza A were neutropenia,febrile convulsion and leucopenia.The more frequent complications of influenza B were pneumonia and viral encephalitis.The lymphocyte percentage in children with influenza A was lower than that in children with influenza B.The fever symptoms remission time and hospitalization time of children with influenza A treated with Peramivir were significantly shorter than those of children with influenza B.

Key words： Influenza A Influenza B Children Clinical characteristics Peramivir

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2023/V30/I21/57

[1]	刘洁，邓志宏，罗万军，等.儿童腺病毒与流感病毒感染临床特征[J].中华医院感染学杂志，2023，33（1）：157-160.
[2]	中华医学会儿科学分会呼吸学组，国家呼吸系统疾病临床医学研究中心.儿童流感诊断与治疗专家共识（2020 年版）[J].中华实用儿科临床杂志，2020，35（17）：1281-1288.
[3]	Wang X，Li Y，O'Brien KL，et al.Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018：a systematic review and modelling study[J].Lancet Glob Health，2020，8（4）：e497-e510.
[4]	Palomba E，Castelli V，Renisi G，et al.Antiviral Treatments for Influenza[J].Semin Respir Crit Care Med，2021，42（6）：859-872.
[5]	Liu JW，Lin SH，Wang LC，et al.Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children：A Systematic Review and Network Metaanalysis[J].JAMA Netw Open，2021，4（8）：e2119151.
[6]	Mawatari M，Saito R，Hibino A，et al.Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza[J].PLoS One，2019，14（11）：e0224683.
[7]	中华人民共和国国家卫生健康委员会，国家中医药管理局.流行性感冒诊疗方案（2020 年版）[J].中华临床感染病杂志，2020，13（6）：401-411.
[8]	中华人民共和国国家卫生健康委员会.儿童血细胞分析参考区间[EB/OL]（2021-5-17）.http：//www.nhc.gov.cn/wjw/s9492/202105/19e3455a5dfe47e7a84756dd3968e475.shtml.
[9]	Lee J，Park JH，Jwa H，et al.Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza：Systematic Review and Meta-Analysis[J].Yonsei Med J，2017，58（4）：778-785.
[10]	Palomba E，Castelli V，Renisi G，et al.Antiviral Treatments for Influenza[J].Semin Respir Crit Care Med，2021，42（6）：859-872.
[11]	Chen HD，Wang X，Yu SL，et al.Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia：A Randomized Controlled Study[J].Open Forum Infect Dis，2020，8（1）：ofaa562.
[12]	Azziz Baumgartner E，Dao CN，Nasreen S，et al.Seasonality，timing，and climate drivers of influenza activity worldwide[J].J Infect Dis，2012，206（6）：838-846.
[13]	刘玲，吴佳瑾，徐馨雨，等，2017—2020 年上海市松江区乙型流感病毒病原学特征分析[J].中华实验和临床病毒学杂志，2022，36（6）：671-677.
[14]	谭章平，喻臻，唐云，等.新型冠状病毒肺炎疫情防控措施对重庆市流行性感冒传播和流行的影响[J].中国热带医学，2023，23（4）：1-8.
[15]	国家呼吸系统疾病临床医学研究中心.儿童流感防治30问[J].中华实用儿科临床杂志，2020，35（17）：1292-1298.
[16]	邢正，付丹.儿童流感病毒感染临床特点及重症病例危险因素分析[J].中国小儿急救医学，2021，28（5）：376-379.
[17]	高兵，黄铭，张辉，等.血细胞参数及比值在儿童甲型流感病毒感染中的应用价值[J].临床血液学杂志，2020，33（4）：248-252.
[18]	曹义，胡伟强，李金玉，等.外周血CRP、NLR、PLR、LMR检测在甲/乙型流感患者中的临床应用[J].国际医药卫生导报，2020，26（24）：3816-3819.
[19]	Swierczyńska M，Mirowska-Guzel DM，Pindelska E.Antiviral Drugs in Influenza[J].Int J Environ Res Public Health，2022，19（5）：3018.
[20]	Palomba E，Castelli V，Renisi G，et al.Antiviral Treatments for Influenza[J].Semin Respir Crit Care Med，2021，42（6）：859-872.
[21]	HsiehYH，DugasAF，LoVecchioF，et al.IntravenousPeramivir vs oral oseltamivir in high-risk emergency department patients with influenza：Resultsfrom a pilot randomized controlled study[J].Influenza Other Respir Viruses，2021，15（1）：121-131.
[22]	McLaughlin MM，Skoglund EW，Ison MG.Peramivir：an intravenous neuraminidase inhibitor[J].Expert Opin Pharmacother，2015，16（12）：1889-1900.
[23]	Ishiguro N，Koseki N，Kaiho M，et al.Clinical effectiveness of four neuraminidase inhibitors（oseltamivir，zanamivir，laninamivir，and peramivir）for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan[J].J Infect Chemother，2018，24（6）：449-457.
[24]	Chen HD，Wang X，Yu SL，et al.Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia：A Randomized Controlled Study[J].Open Forum Infect Dis，2020，8（1）：ofaa562.
[25]	John V，Stephanie P，Rajasekaran A，et al.Single Dose ⅣPeramivir is Safe and Effective in the Treatment of Pediatric Influenza[J].Open Forum Infect Dis，2017，4（Suppl 1）：S694.